# [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

> **NCT05619016** · PHASE2 · UNKNOWN · sponsor: **Karolinska University Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Esophageal Neoplasms
- Gastric Neoplasms Malignant
- Breast Cancer
- HER2-positive Gastric Cancer

## Interventions

- **DIAGNOSTIC_TEST:** [68Ga]Ga-ABY-025 PET
- **DIAGNOSTIC_TEST:** Biopsy and analysis of HER2 expression

## Key facts

- **NCT ID:** NCT05619016
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-23
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05619016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05619016, "[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05619016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*